Formycon AG
XETRA:FYB

Watchlist Manager
Formycon AG Logo
Formycon AG
XETRA:FYB
Watchlist
Price: 52.5 EUR 2.34%
Market Cap: 927.2m EUR
Have any thoughts about
Formycon AG?
Write Note

Formycon AG
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Formycon AG
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Formycon AG
XETRA:FYB
Total Equity
€502.8m
CAGR 3-Years
96%
CAGR 5-Years
72%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Total Equity
€20.2B
CAGR 3-Years
145%
CAGR 5-Years
138%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Total Equity
-€261.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CureVac NV
NASDAQ:CVAC
Total Equity
€516.9m
CAGR 3-Years
-10%
CAGR 5-Years
74%
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Total Equity
€225.1m
CAGR 3-Years
37%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Total Equity
€527.5m
CAGR 3-Years
9%
CAGR 5-Years
1%
CAGR 10-Years
1%
No Stocks Found

Formycon AG
Glance View

Market Cap
927m EUR
Industry
Biotechnology

Formycon AG engages in the manufacture of biosimilar drugs and formulations. The company is headquartered in Martinsried, Bayern and currently employs 159 full-time employees. The company went IPO on 2010-12-20. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The firm focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.

FYB Intrinsic Value
77.46 EUR
Undervaluation 32%
Intrinsic Value
Price

See Also

What is Formycon AG's Total Equity?
Total Equity
502.8m EUR

Based on the financial report for Dec 31, 2023, Formycon AG's Total Equity amounts to 502.8m EUR.

What is Formycon AG's Total Equity growth rate?
Total Equity CAGR 5Y
72%

Over the last year, the Total Equity growth was 41%. The average annual Total Equity growth rates for Formycon AG have been 96% over the past three years , 72% over the past five years .

Back to Top